Suppr超能文献

相似文献

1
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Gut. 2023 Jan;72(1):129-140. doi: 10.1136/gutjnl-2021-325918. Epub 2022 Feb 23.
4
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Gastroenterology. 2016 Dec;151(6):1192-1205. doi: 10.1053/j.gastro.2016.09.001. Epub 2016 Sep 7.
5
CEP55: Implications for Immunotherapy and Survival in Hepatocellular Carcinoma.
Comb Chem High Throughput Screen. 2024 Jun 6. doi: 10.2174/0113862073298525240522104104.
6
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
7
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
A Novel RNA Methylation-Related Prognostic Signature and its Tumor Microenvironment Characterization in Hepatocellular Carcinoma.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241276895. doi: 10.1177/15330338241276895.
9
Hyperactivation of β-catenin signal in hepatocellular carcinoma recruits myeloid-derived suppressor cells through PF4-CXCR3 axis.
Cancer Lett. 2024 Apr 1;586:216690. doi: 10.1016/j.canlet.2024.216690. Epub 2024 Feb 1.
10
Molecular phenotypic linkage between N-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma.
J Cancer Res Clin Oncol. 2023 Aug;149(10):6901-6916. doi: 10.1007/s00432-023-04589-2. Epub 2023 Feb 24.

引用本文的文献

5
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.
Immunotargets Ther. 2025 Jun 25;14:631-654. doi: 10.2147/ITT.S528709. eCollection 2025.
6
Expression landscape of epigenetic genes in human hepatocellular carcinoma.
J Physiol Biochem. 2025 Jun 12. doi: 10.1007/s13105-025-01095-6.
7
Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy.
Cell Mol Immunol. 2025 Jun 11. doi: 10.1038/s41423-025-01308-4.
8
The Synergistic Mechanisms and Prospects of Transarterial Chemoembolization Combined with Immunotherapy for Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2025 Apr 30;12:841-854. doi: 10.2147/JHC.S514881. eCollection 2025.
9
Characterization of T-Cell Receptor Profiles Predicts Survival Situation in Patients with Hepatocellular Carcinoma.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251329699. doi: 10.1177/15330338251329699. Epub 2025 Mar 28.

本文引用的文献

1
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Gastroenterology. 2023 Jan;164(1):72-88.e18. doi: 10.1053/j.gastro.2022.09.005. Epub 2022 Sep 12.
4
Immunotherapies for hepatocellular carcinoma.
Nat Rev Clin Oncol. 2022 Mar;19(3):151-172. doi: 10.1038/s41571-021-00573-2. Epub 2021 Nov 11.
7
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24.
8
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.
Nat Rev Cancer. 2021 May;21(5):298-312. doi: 10.1038/s41568-021-00339-z. Epub 2021 Mar 9.
9
Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
J Hepatol. 2021 Jun;74(6):1386-1397. doi: 10.1016/j.jhep.2021.01.017. Epub 2021 Jan 21.
10
Hepatocellular carcinoma.
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验